Sanegene Bio
Clinical-stage biotechnology company (founded 2021) developing RNA interference (RNAi) therapeutics. Operates R&D in Boston, Shanghai and Suzhou. Develops optimized siRNA payloads and tissue-selective delivery platforms to enable infrequent subcutaneous dosing for indications in complement-mediated diseases, cardiovascular disease, obesity/metabolic disorders and other chronic indications. Engages in clinical development, regulatory interactions, and industry collaborations/licensing.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Liver-directed GalNAc-conjugated siRNA targeting complement C3 (clinical-stage)
Hepatocyte-targeted siRNA designed to silence C3 mRNA to reduce hepatic C3 production and downstream complement activity; evaluated in Phase 1 and Phase 2 studies for complement-mediated kidney and hematologic diseases.
Liver-directed siRNA targeting complement Factor B (CFB) (early clinical)
RNAi therapeutic designed to silence CFB mRNA in hepatocytes to inhibit the alternative complement pathway; progressed to Phase 1 and approved for clinical evaluation in blood disorder indications.
Liver-directed siRNA targeting AGT for hypertension (early clinical)
GalNAc-conjugated siRNA designed to silence angiotensinogen (AGT) mRNA in the liver to achieve durable reductions in AGT and preliminary blood pressure lowering effects; clinical data reported in first-in-human studies.
Liver-directed siRNA targeting INHBE for obesity/metabolic disease (early clinical)
GalNAc-conjugated siRNA to silence INHBE mRNA in hepatocytes to reduce Activin E signaling, investigated for selective fat loss, preservation of lean mass and metabolic improvements; IND/CTA approvals and Phase 1 initiated.
Liver-directed GalNAc-conjugated siRNA targeting complement C3 (clinical-stage)
Hepatocyte-targeted siRNA designed to silence C3 mRNA to reduce hepatic C3 production and downstream complement activity; evaluated in Phase 1 and Phase 2 studies for complement-mediated kidney and hematologic diseases.
Liver-directed siRNA targeting complement Factor B (CFB) (early clinical)
RNAi therapeutic designed to silence CFB mRNA in hepatocytes to inhibit the alternative complement pathway; progressed to Phase 1 and approved for clinical evaluation in blood disorder indications.
Liver-directed siRNA targeting AGT for hypertension (early clinical)
GalNAc-conjugated siRNA designed to silence angiotensinogen (AGT) mRNA in the liver to achieve durable reductions in AGT and preliminary blood pressure lowering effects; clinical data reported in first-in-human studies.
Liver-directed siRNA targeting INHBE for obesity/metabolic disease (early clinical)
GalNAc-conjugated siRNA to silence INHBE mRNA in hepatocytes to reduce Activin E signaling, investigated for selective fat loss, preservation of lean mass and metabolic improvements; IND/CTA approvals and Phase 1 initiated.
Services
Discovery and early optimization of tissue-selective RNAi molecules and grant of development/commercialization licenses to partners; models include discovery partnerships, upfront payments, milestone frameworks and royalty arrangements.
End-to-end early clinical development capabilities including study design, site partnerships, investigator-led trials, PK/PD analysis and regulatory filings to advance investigational RNAi therapeutics.
Discovery and early optimization of tissue-selective RNAi molecules and grant of development/commercialization licenses to partners; models include discovery partnerships, upfront payments, milestone frameworks and royalty arrangements.
End-to-end early clinical development capabilities including study design, site partnerships, investigator-led trials, PK/PD analysis and regulatory filings to advance investigational RNAi therapeutics.
Expertise Areas
- RNAi/siRNA therapeutic development
- Targeted delivery to liver and extrahepatic tissues
- Oligonucleotide chemistry and payload optimization
- Preclinical to early clinical translation
Key Technologies
- RNA interference (siRNA)
- GalNAc-conjugation for hepatocyte targeting
- Ligand- and enhancer-assisted receptor-mediated delivery
- Bispecific (multi-target) siRNA constructs
News & Updates
Interim Phase 2 results of a liver-targeted siRNA targeting complement C3 in IgAN, C3G and IC-MPGN presented as a late-breaking research poster (data on UPCR, eGFR, serum C3 and complement activity).
Announcement of acceptance to present interim Phase 2 results of a liver-targeted GalNAc-siRNA targeting complement C3 at ASN Kidney Week 2026 (poster details and presenter listed).
Phase 1 results showing dose-dependent, sustained reduction in serum C3 and inhibition of alternative pathway activity; favorable safety profile reported.
Exclusive worldwide license granted for one RNAi program; upfront and milestone/royalty terms disclosed and partner responsible for subsequent clinical development and commercialization.
Global collaboration to advance RNAi candidates for metabolic disease targets; SanegeneBio responsible for discovery/optimization, Lilly responsible for IND-enabling studies and later development/commercialization.
Closed Series B financing to advance clinical-stage assets and expand development globally.
Interim Phase 2 results of a liver-targeted siRNA targeting complement C3 in IgAN, C3G and IC-MPGN presented as a late-breaking research poster (data on UPCR, eGFR, serum C3 and complement activity).
Announcement of acceptance to present interim Phase 2 results of a liver-targeted GalNAc-siRNA targeting complement C3 at ASN Kidney Week 2026 (poster details and presenter listed).
Phase 1 results showing dose-dependent, sustained reduction in serum C3 and inhibition of alternative pathway activity; favorable safety profile reported.
Exclusive worldwide license granted for one RNAi program; upfront and milestone/royalty terms disclosed and partner responsible for subsequent clinical development and commercialization.
Global collaboration to advance RNAi candidates for metabolic disease targets; SanegeneBio responsible for discovery/optimization, Lilly responsible for IND-enabling studies and later development/commercialization.
Closed Series B financing to advance clinical-stage assets and expand development globally.